Tenax Therapeutics, Inc. (TENX) |
|
0.52 -0.006 (-1.14%)
|
03-24 16:00 |
|
Open: |
0.49 |
Pre. Close: |
0.526 |
|
High:
|
0.5386 |
Low:
|
0.4801 |
|
Volume:
|
1,553,210 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:30:27 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.87  One year: 1.08 |
| Support: |
Support1: 0.45 Support2: 0.37 |
| Resistance: |
Resistance1: 0.74 Resistance2: 0.93 |
| Pivot: |
0.56 |
| Moving Average: |
MA(5): 0.56  MA(20): 0.59
MA(100): 1.85 MA(250): 5.46 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 27.3 %D(3): 35.6 |
| RSI: |
RSI(14): 34.9 |
| 52-week: |
High: 16.95 Low: 0.32 |
| Average Vol(K): |
3-Month: 4,102 (K) 10-Days: 10,164 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TENX ] has closed above bottom band by 27.1%. Bollinger Bands are 79.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.54 - 0.54 |
0.54 - 0.55 |
|
Low:
|
0.47 - 0.48 |
0.48 - 0.48 |
|
Close:
|
0.51 - 0.52 |
0.52 - 0.53 |
|
Company Description |
|
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. |
Headline News |
Fri, 24 Mar 2023
Tenax Therapeutics Inc. (TENX) Stock Records -80.73% Quarterly ... - The News Heater
Wed, 22 Mar 2023
Tenax Therapeutics Granted US Patent Covering Use of IV ... - Investing.com India
Wed, 22 Mar 2023
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - Yahoo Finance
Mon, 13 Mar 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Wed, 08 Mar 2023
Roth MKM Initiates Coverage of Tenax Therapeutics (TENX) with ... - Nasdaq
Fri, 10 Feb 2023
Should You Sell Tenax Therapeutics Inc (TENX) Stock Friday Morning? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
4.5 (%) |
|
% Held by Institutions
|
4 (%) |
|
Shares Short
|
102 (K) |
|
Shares Short P.Month
|
30 (K) |
Stock Financials |
|
EPS
|
-1.33 |
|
EPS Est Next Qtl
|
-0.08 |
|
EPS Est This Year
|
-0.37 |
|
EPS Est Next Year
|
-0.29 |
|
Book Value (p.s.)
|
0.37 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-96.3 |
|
Return on Equity (ttm)
|
-209.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-4.59 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-12 (M) |
|
Levered Free Cash Flow
|
-7 (M) |
Stock Valuations |
|
PE Ratio
|
-0.4 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.4 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.1 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-02-25 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
